Savant Capital LLC Has $451,000 Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Savant Capital LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 514 shares of the biopharmaceutical company’s stock after purchasing an additional 117 shares during the quarter. Savant Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $451,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Eudaimonia Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals by 1.2% during the 4th quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock worth $803,000 after buying an additional 11 shares during the last quarter. Drive Wealth Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 4.0% in the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 12 shares during the last quarter. MCF Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 12 shares in the last quarter. Sutton Wealth Advisors Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 13 shares during the last quarter. Finally, Clearview Wealth Advisors LLC increased its position in Regeneron Pharmaceuticals by 1.5% during the 4th quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock worth $751,000 after purchasing an additional 13 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 2.1 %

Shares of REGN stock opened at $957.00 on Monday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The stock has a 50 day simple moving average of $943.75 and a two-hundred day simple moving average of $897.24. The company has a market cap of $105.04 billion, a P/E ratio of 28.27, a PEG ratio of 2.74 and a beta of 0.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $10.96 EPS. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Marion Mccourt sold 358 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $967.50, for a total transaction of $346,365.00. Following the transaction, the executive vice president now owns 13,431 shares in the company, valued at $12,994,492.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the sale, the director now owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Marion Mccourt sold 358 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $967.50, for a total transaction of $346,365.00. Following the transaction, the executive vice president now owns 13,431 shares in the company, valued at approximately $12,994,492.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 9,095 shares of company stock worth $8,729,766. 8.83% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research analyst reports. TD Cowen raised their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price objective on the stock. Barclays increased their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research report on Tuesday, January 23rd. Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. Finally, UBS Group raised their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $981.71.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.